Dong-A ST is expected to create synergy with its item Teribone by taking charge of the sale of Sanofi's osteoporosis treatment, Actonel.

Dong-A ST will supply Sanofi-Aventis' osteoporosis treatment, Actonel, starting in October.
Actonel is a bisphosphonate-based treatment that inhibits bone absorption. Since its launch in 2003, it has ranked 1st and 2nd in market share, but the amount of prescription has been gradually decreasing due to the emergence of new drugs and changes in treatment strategies. It has been out of stock due to issues such as relocation of manufacturing plants.

Sanofi stopped supplying Actonel 5mg due to low sales in April, and stopped supplying Actonel 35mg thi